0.10Open0.10Pre Close0 Volume962 Open Interest2.50Strike Price0.00Turnover4244.97%IV24.40%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.3078Delta0.6028Gamma20.90Leverage Ratio-6.6002Theta0.0000Rho6.43Eff Leverage0.0000Vega
Caribou Biosciences Stock Discussion
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...
No comment yet